CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of ...
Phase 2
Providence, Rhode Island, United States and 3 other locations
adenocarcinoma. Participants will receive immunotherapy (cemiplimab) which activates the body's immune system to attack cancer cells. Cemip...
Phase 2
Providence, Rhode Island, United States and 1 other location
This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer.The names of...
Phase 2
Boston, Massachusetts, United States
combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).Two cohorts will be enrolled in parallel in this study:...
Phase 1, Phase 2
Boston, Massachusetts, United States and 26 other locations
will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, ...
Phase 1, Phase 2
Boston, Massachusetts, United States of America and 5 other locations
The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant t...
Phase 2
Boston, Massachusetts, United States and 2 other locations
as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma...
Phase 2
Boston, Massachusetts, United States and 47 other locations
mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer tre...
Phase 2
Boston, Massachusetts, United States and 44 other locations
participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...
Phase 1, Phase 2
Boston, Massachusetts, United States and 66 other locations
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-...
Phase 1
Boston, Massachusetts, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal